Pharmacokinetics of Treprostinil Sodium Administered by 28-Day Chronic Continuous Subcutaneous Infusion

Journal of Clinical Pharmacology

Volumn 44, Issue 5, 2004, Pages 503-509

  Wade, Michael ^a   Baker, F Jo ^a   Roscigno, Robert ^a   DellaMaestra, Wayne ^a   Arneson, Carl P ^a   Hunt, Thomas L ^c   Lai, Allen A ^b  

^a UNITED THERAPEUTICS CORPORATION   (United States)

^b CPKD Solutions   (United States)

^c Pharmaceutical Product Development   (United States)

Author keywords

Chronic pharmacokinetics; Prostacyclin; Pulmonary arterial hypertension; Remodulin ; Subcutaneous infusion; Treprostinil sodium

Indexed keywords

UNIPROST;

ADULT; AKATHISIA; ANOREXIA; ARTHRALGIA; ARTICLE; ASTHENIA; BLOOD SAMPLING; CHRONIC DRUG ADMINISTRATION; CIRCADIAN RHYTHM; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DIZZINESS; DOSE CALCULATION; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG SAFETY; FEMALE; HEMATOMA; HUMAN; INJECTION SITE; LINEAR REGRESSION ANALYSIS; LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; MYALGIA; NAUSEA; NORMAL HUMAN; OPEN STUDY; PAIN; PARAMETER; PLASMA CLEARANCE; QUANTITATIVE ANALYSIS; SIDE EFFECT; SKIN MANIFESTATION; STEADY STATE; VALIDATION PROCESS; VARIANCE;

ADOLESCENT; ADULT; CIRCADIAN RHYTHM; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; EPOPROSTENOL; FEMALE; HALF-LIFE; HUMANS; INFUSION PUMPS; INJECTIONS, SUBCUTANEOUS; ISOTONIC SOLUTIONS; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; TIME FACTORS;

EID: 1942443913     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1177/0091270004264638     Document Type: Article

References (17)

1. Barst RJ, Rubin LJ, Long WA, McGoon MD, Rich S, Badesch DB, et al: A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl J Med 1996;334:296-302.
2. McLaughlin VV, Genthner DE, Panella MM, Rich S: Reduction in pulmonary vascular resistance with long-term epoprostenol (prostacyclin) therapy in primary pulmonary hypertension. N Engl J Med 1998;338:273-277.
3. Badesch DB, Tapson VF, McGoon MD, Brundage BH, Rubin LJ, Wigley FM, et al: Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease: a randomized, controlled trial. Ann Intern Med 2000;132:425-434.
4. Sanchez O, Humbert M, Sitbon O, Simonneau G: Treatment of pulmonary hypertension secondary to connective tissue disease. Thorax 1999;54:273-277.
5. Rosenzweig EB, Kerstein D, Barst RJ: Long term prostacyclin for pulmonary hypertension associated congenital heart defects. Circulation 1999;99:1858-1865.
6. McLaughlin VV, Genthner DE, Panella MM, Hess DM, Rich S: Compassionate use of continuous prostacyclin in the management of secondary pulmonary hypertension: a case series. Ann Intern Med 1999;130:740-743.
7. Steffen RP, de la Meta M: The effects of 15AU81, a chemically stable prostacyclin analogue, on the cardiovascular and renin-angiotensin systems of anesthetized dogs. Prostaglandins Leukot Essent Fatty Acids 1991;43:277-286.
8. McNulty MJ, Sailstad JM, Steffen RP: The pharmacokinetics and pharmacodynamics of prostacyclin analogue 15AU81 in anesthetized beagle dog. Prostaglandins Leukot Essent Fatty Acids 1993;48:159-166.
9. Gaine SP, Oudiz R, Rich S, Barst R, Roscigno R: Acute hemodynamic effects of 15AU81, a stable prostacyclin analogue, in severe primary pulmonary hypertension [abstract]. Am J Respir Crit Care Med 1998;157:A595.
10. Graham DR, Keldermans MM, Klemm LW, Semenza NJ, Shafer ML: Infectious complications among patients receiving home intravenous therapy with peripheral, central, or peripherally placed central venous catheters. Am J Med 1991;91:95S-100S.
11. Simmonneau G, Barst RJ, Galie N, Naeije R, Rich S, Bourge RC, et al: Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. Am J Resp Crit Care Med 2002;165(6):800-804.
12. Remodulin® (treprostinil sodium) Injection [product information]. Research Triangle Park, NC: United Therapeutics Corporation, 2002.
13. Wade M, Baker FJ, Roscigno R, DellaMaestra W, Hunt TL, Lai AA: Absolute bioavailability and pharmacokinetics of treprostinil sodium administered by acute subcutaneous infusion. J Clin Pharmacol 2004;44:83-88.
14. Nadler JL, Yamamoto JV: Diurnal variation and exercise induced changes of prostacyclin in man. Prostaglandins Leukot Med 1986;22(1):71-78.
15. Savran B, Gorgun CZ, Zengil H: Circadian reactivity rhythm of rat gastric mucosa to restraint-cold stress and indomethacin: temporal variation in the protective effect of iloprost. Chronobiol Int 1997;14(6):575-563.
16. Yosipovitch G, Yosipovitch Z, Harell D, Ashkenazi I, Erman A: Diurnal rhythm of prostanoid secretion from bone/marrow organ in the rat. Bone 1995;17(1):79-83.
17. Wennmalm A, Benthin G, Granstrom EF, Persson L, Winell S: 2,3-Dinor metabolites of thromboxane A2 and prostacyclin in urine from healthy human subjects: diurnal variation and relation to 24h excretion. Clin Sci (Lond) 1992;83(4):461-465.